“Epizyme’s loss per share of $0.63 was less than our estimated $(0.75). This primarily resulted from lower than estimated operating expense of $38.1 million compared to our estimated $44.5 million. Our outlook remains basically unchanged for 2018-2022.”,” the firm’s analyst wrote.
A number of other equities analysts have also weighed in on EPZM. Zacks Investment Research raised Epizyme from a hold rating to a buy rating and set a $16.00 price objective on the stock in a research note on Wednesday, July 12th. BidaskClub lowered Epizyme from a hold rating to a sell rating in a research note on Wednesday, July 19th. Royal Bank Of Canada set a $20.00 price objective on Epizyme and gave the stock a buy rating in a research note on Saturday, August 5th. HC Wainwright reissued a buy rating on shares of Epizyme in a research note on Monday, August 7th. Finally, Leerink Swann reissued an outperform rating and set a $28.00 price objective (down previously from $31.00) on shares of Epizyme in a research note on Wednesday, August 9th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $22.67.
Epizyme (EPZM) traded down $0.35 during midday trading on Thursday, reaching $14.20. The company’s stock had a trading volume of 685,893 shares, compared to its average volume of 514,189.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.02. research analysts anticipate that Epizyme will post -2.25 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Epizyme’s (EPZM) “Buy” Rating Reiterated at Cann” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.com-unik.info/2017/11/05/epizymes-epzm-buy-rating-reiterated-at-cann.html.
In other news, Director David M. Mott acquired 200,000 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The shares were purchased at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the acquisition, the director now owns 6,000 shares of the company’s stock, valued at $91,500. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $16.44, for a total value of $246,600.00. Following the completion of the sale, the insider now owns 23,123 shares in the company, valued at approximately $380,142.12. The disclosure for this sale can be found here. Insiders sold 45,000 shares of company stock worth $733,950 in the last 90 days. Company insiders own 25.20% of the company’s stock.
Several hedge funds have recently bought and sold shares of the stock. Alps Advisors Inc. raised its holdings in shares of Epizyme by 9.1% in the 3rd quarter. Alps Advisors Inc. now owns 57,472 shares of the biopharmaceutical company’s stock valued at $1,095,000 after buying an additional 4,797 shares during the period. NEA Management Company LLC raised its holdings in shares of Epizyme by 3.2% in the 3rd quarter. NEA Management Company LLC now owns 6,460,851 shares of the biopharmaceutical company’s stock valued at $123,079,000 after buying an additional 200,000 shares during the period. Swiss National Bank raised its holdings in shares of Epizyme by 25.5% in the 3rd quarter. Swiss National Bank now owns 83,700 shares of the biopharmaceutical company’s stock valued at $1,594,000 after buying an additional 17,000 shares during the period. Fox Run Management L.L.C. purchased a new stake in shares of Epizyme in the 3rd quarter valued at $223,000. Finally, Lord Abbett & CO. LLC purchased a new stake in shares of Epizyme in the 2nd quarter valued at $9,726,000. Hedge funds and other institutional investors own 72.20% of the company’s stock.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
What are top analysts saying about Epizyme Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Epizyme Inc. and related companies.